Blog

Casdin Capital to Become Shareholder in BioLife Solutions – Investment Firm to Purchase Shares from Existing Holder

On April 9, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, (“BioLife” or the “Company”), announced that Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second…

BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially 2018 Revenue Guidance Revised Upward

On April 2, 2018, BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary revenue for the three months ended March 31, 2018. First quarter 2018 preliminary revenue from sales of BioLife’s proprietary CryoStor® and HypoThermosol® biopreservation media products reached $3.8 million,…

BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies

12 Additional Pending Patent Applications Submitted for evo® Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application   On March 26, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologies, the leading developer of smart,…

PDA Presentation: Cell Viability After Cryopreservation

On March 20, 2018 Dr. Brian Hawkins, Scientific Applications Director, will be presenting a poster entitled, “The prats and pitfalls of assessing cell viability after cryopreservation,” at the 2018 PDA Annual Meeting in Orlando, FL.  The poster describes how common methods of determining cell viability under normal conditions are inconsistent and inaccurately represent cell health…

BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research

On March 13, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation. In multiple comparisons of preservation efficacy of patient-derived xenograft (PDX) tumors,…

BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results

BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results  Revenue Increased 39% for the Quarter and 34% for the Year Achieves Positive Cash Flow from Operations for the Year Reaffirms Guidance for 2018 Operating Profit On March 8, 2018 BioLife Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue…

BioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018

BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media (“BioLife” or the “Company”), announced that the Company’s fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018, and that the Company will host a…

BioLife Solutions Executes OEM Agreement with MilliporeSigma

BioLife Solutions Executes OEM Agreement with MilliporeSigma  Private Labeled CryoStor® Cell Freeze Media and HypoThermosol® Cell and Tissue Storage and Shipping Media Distributed to Worldwide Biotech Research Market On February 13, 2018 BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has…

CGTI Alireza Article Blog Post

Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno- modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during biopreservation/stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe.…